Redx Pharma merges with Skye Bioscience via reverse merger, rebranding as Fibrx Therapeutics on Nasdaq, raising $125M to advance ROCK inhibitor RXC008 for Crohn's disease.
Lisa Anson, Redx Pharma CEO
August 14, 2026 11:30 AM EDT
Redx tries again at reverse merger, with Skye this time, as alternative route gains steam
UK fibrosis biotech Redx Pharma is making another go at a reverse merger, after its last attempt was axed in 2023.
The …
Atea's BEM/RZR matches Gilead's Epclusa in Phase 3; AbCellera partners with Vertex for $28M; LB Pharma raises $150M for…
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere,…
In a remarkable turnaround, Replimune has reversed the fortune of its melanoma therapy, winning FDA approval after two prior…
Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its…
Ambros Therapeutics will take the Nasdaq spot of Werewolf Therapeutics, a cancer biotech that has been exploring strategic…
Caldera-Synlogic and Vidya-Processa ink reverse mergers with Bain-backed placements, advancing a TL1A bispecific and a BTK…
